UCB (OTCMKTS:UCBJF) Trading Down 5.9% – What’s Next?

UCB SA (OTCMKTS:UCBJF) fell 5.9% during trading on Thursday . The company traded as low as $248.60 and last traded at $248.60. 69 shares were traded during trading, a decline of 90% from the average session volume of 725 shares. The stock had previously closed at $264.09.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on UCBJF shares. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

UCB Trading Up 2.7%

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The stock’s 50-day simple moving average is $274.31 and its two-hundred day simple moving average is $290.79.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.